Ariad Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Ariad Pharmaceuticals (ARIA)

Q2 2012 Earnings Call

August 02, 2012 8:30 am ET

Executives

Maria E. Cantor - Senior Vice President of Corporate Affairs

Harvey J. Berger - Principal Founder, Chairman of the Board, Chief Executive Officer, President and Chairman of Executive Committee

Edward M. Fitzgerald - Chief Financial Officer, Principal Accounting Officer, Executive Vice President and Treasurer

Analysts

Matthew Harrison - UBS Investment Bank, Research Division

Y. Katherine Xu - William Blair & Company L.L.C., Research Division

Ryan Martins - Lazard Capital Markets LLC, Research Division

Michael J. Yee - RBC Capital Markets, LLC, Research Division

Joel D. Sendek - Stifel, Nicolaus & Co., Inc., Research Division

Eileen Flowers - Jefferies & Company, Inc., Research Division

Ying Huang - Barclays Capital, Research Division

Michael G. King - Rodman & Renshaw, LLC, Research Division

Philip Nadeau - Cowen and Company, LLC, Research Division

Howard Liang - Leerink Swann LLC, Research Division

Karen E. Jay - JP Morgan Chase & Co, Research Division

Rachel L. McMinn - BofA Merrill Lynch, Research Division

Echo Yinghui He - Maxim Group LLC, Research Division

Presentation

Operator

Thank you for holding for ARIAD Pharmaceuticals Second Quarter 2012 Investor Conference Call. [Operator Instructions] Please be advised that this call is being taped at the company's request and will be archived on the company's website for 3 weeks from today. At this time, I'd like to introduce Ms. Maria Cantor, ARIAD's Senior Vice President, Corporate Affairs. Please go ahead.

Maria E. Cantor

Good morning, and thank you for joining us. This morning, we report on financial results and corporate developments for the second quarter of 2012. Dr. Harvey Berger, our Chairman and Chief Executive Officer; and Mr. Ed Fitzgerald, our Executive Vice President and Chief Financial Officer are joining me on this call.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)